U.S. Food and Drug Administration Notice: Archived Document. The content in this document is provided on the FDA’s website for reference purposes only.

Slides:



Advertisements
Similar presentations
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDAs website for reference purposes only. It.
Advertisements

Development of Guidance Documents Jennifer Scharpf, M. P. H
Epidemiology of HIV-2 infection in the U.S, Lata Kumar MS, MPH Richard Selik MD Division of HIV/AIDS Prevention National Center for HIV/AIDS,
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Dengue Virus and Its Risk to the U.S. Blood Supply
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Parvovirus B19 NAT for Whole Blood and Source Plasma Introduction and Background Mei-ying W Yu, PhD DH/OBRR/CBER/FDA 75 th Blood Products Advisory Committee.
Am I affected by AIDS?.
CBER U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
An important message to blood donors Please read this BEFORE you donate blood.
Top 5 OPTN Policy Violations
21 August 2015 Samreen Ijaz Virus Reference Department Health Protection Agency Indigenous HEV infection in the UK: a hazard for blood donation?
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
HIV & AIDS. HIV INFECTION HIV-The most serious incurable STI HIV-Human Immunodeficiency Virus.
Glencoe Making Life Choices Section 2 HIV and AIDS Chapter 16 Sexually Transmitted Diseases 1 > HOME Content Vocabulary Pneumocystis carinii.
+ Dr. Megan Rowley Consultant in Transfusion Medicine Blood Transfusion.
IN THE NAME OF GOD Blood Safety S. AMINI KAFI ABAD CLINICAL AND ANATOMICAL PATHOLOGIST IRANIAN BLOOD TRANSFUSION ORGANIZATION(IBTO) RESEARCH CENTER June.
Microbiology Mrs. McGuire VIRAL DISEASES. SMALLPOX Caused by the variola virus Except for laboratory stockpiles, the virus has been eliminated Transmitted.
21th VHPB meeting on “Prevention of viral hepatitis in Italy: lessons learnt and the way forward” Catania, 7-8 november 2002 RESIDUAL RISK OF TRANSFUSION-
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Challenges in evaluating and changing donor criteria Dr. Mindy Goldman Transfusion Medicine Residents April 30, 2008.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Approval Criteria for Assays for Testing Blood Donors for West Nile Virus Robin Biswas, M.D. CBER, FDA Blood Products Advisory Committee Meeting March.
Current Status of Issues Related to West Nile virus testing and donor screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
Progress in West Nile virus Testing and Donor Screening Hira Nakhasi, Ph.D. Director, DETTD/OBRR CBER, FDA.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Risk Assessments: Models for Estimating the Risk of Transmitting TSE by Human Tissue Intended for Transplantation Rolf E. Taffs, Ph.D. Center for Biologics.
S The European Up-Front Risk Assessment Tool (EUFRAT) The European Up-Front Risk Assessment Tool (EUFRAT) (EUFRAT)
1 B19 Testing of Plasma for Fractionation: Current Thinking Mei-ying W Yu, PhD Division of Hematology CBER/FDA SoGAT XVII May 26-27, 2004.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Abbreviated Donor History Questionnaire: Background and Introduction Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee March 2005.
BLOOD TRANSFUSION SAFETY: PROGRESS REPORT 142 nd Session of the Executive Committee June 2008, Washington DC Pan American Health Organization 142.
Revised Recommendations for the Assessment of Donor Suitability: West Nile Virus Sharyn Orton, Ph.D. OBRR/CBER/FDA Blood Products Advisory Committee Meeting.
Annotating Text. 9/19/12 Do Now: 1) Read the abstract of Scientific Peer reviewed journal. What words or phrases did you find confusing? 2) Take out your.
CURRENT HEALTH PROBLEMS IN STUDENT'S HOME SOUNTRIES HEPATITIS B IN MALAYSIA MOHD ZHARIF ABD HAMID AMINUDDIN BAKI AMRAN.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Validation of Nucleic Acid and Serological Tests to Screen Blood and Plasma donors for Acute infection with West Nile virus Hira Nakhasi, Ph.D. Director,
Filoviruses. Filoviruses (Filoviridae) Marburg and Ebola viruses filamentous, enveloped, negative-strand RNA viruses. These agents cause severe or fatal.
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary for FDA’s BPAC July 2010 Jerry A. Holmberg, Ph.D. Senior Advisor for Blood.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection - Update - Alan E. Williams, Ph.D. Director,
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
CHRONIC VIRAL HEPATITIS CAUSES. HEPATITIS B Originally known as “serum hepatitis”. Percutaneous inoculation- long been recognized as the route of transmission.
Transmission through blood bodily fluids What is a Virus a microscopic parasitic organism cannot live without host cell DNA or RNA Take over host cell.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
HHS Secretary’s Advisory Committee on Blood Safety and Availability Summary of November 2010 ACBSA for FDA’s BPAC December 2010 CDR Richard Henry, USPHS.
CBER Update on status of West Nile virus test, lot release and validation panel development Indira Hewlett, Ph.D CBER/FDA Blood Products Advisory Committee.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.
DEPARTMENT OF HEALTH CENTER FOR BIOLOGICS AND HUMAN SERVICESEVALUATION and RESEARCH AND HUMAN SERVICES EVALUATION and RESEARCH Update on OCTGT Guidance.
Allogeneic donor selection and blood collection by Mohammed Abu-basha 1.
Results from the School Health Policies and Practices Study 2012: How it relates to the work of state school nurse consultants Mary Vernon-Smiley, MD,
Hepatitis B Neha Patel, Rebecca Webber, Lilimae Martin.
FDA’s vCJD Risk Communication on US Plasma- Derived Factor VIII and UK Plasma-Derived Factor XI BPAC April 27, 2007 Mark Weinstein, Ph.D. FDA, Center for.
Bad Blood? An Investigation of the MSM Ban on Blood Donation Lauren Lacy Abstract In 1983, the Food and Drug Administration (FDA), responding to the AIDS.
CBER Current Considerations for Blood Donor Screening for West Nile Virus Pradip N. Akolkar, Ph.D. Maria Rios, Ph.D. DETTD, OBRR Blood Products Advisory.
What is Hep C Dave Stafford.
ZIKA CASES (1/15 -9/7/16) USA- 2,964 total Travel associated 2,920
By: DR.Abeer Omran Consultant pediatric infectious disease
FACILITATOR VERSION Case Four: I just have antibodies to this
To start the presentation, click on this button in the lower right corner of your screen. The presentation will begin after the screen changes and you.
بعض النقاط التي تؤخذ في الحسبان عند تقييم الاستثمارات الزراعية
Professional Organizations
Work out (if you can, simplify your answer) 8 6.
FACILITATOR VERSION Case Four: I just have antibodies to this
Presentation transcript:

U.S. Food and Drug Administration Notice: Archived Document. The content in this document is provided on the FDA’s website for reference purposes only. It was current when produced, but is no longer maintained and may be outdated.

Questionnaire Data for Risk Assessment Presented by: Richard Forshee FDA/CBER/OBE

Donor Questionnaire Issues At least 2 purposes of DHQ –Protect the health of the donor –Identify risk factors to protect the health of recipients Understanding how donors respond to the questionnaire –Complexity of questions varies –Some questions involve personal and sensitive subjects Use of DHQ in risk assessment

Donor Health Example Healthy and Well

Risk Factor Example 1 Transplant

Risk Factor Example 2 Travel to Malarial Area

Risk Factor Example 3 Sexual contact with a prostitute

Use in Risk Assessment Does the questionnaire accurately identify donors with selected risk factors? –Travel to malarial areas Are low-risk donors being deferred because of answers to the questionnaire? –Travel to malarial areas

Hypothetical Example Later in this workshop we will be considering a hypothetical outbreak of a viral hemorrhagic fever caused by an RNA virus in 3 Midwest US states We have constructed an extremely simplified risk assessment to predict the cases of transfusion transmitted hemorrhagic fever Imagine two different DHQ methods of assessing the risk that a donor is infected with the hemorrhagic fever

Two Hypothetical DHQ Instruments

Hypothetical Result

Conclusion Effective DHQ screening is an important component of blood safety We look forward to the presentations in this section